BMP-4 Biomarker Detection for CKD and CAD Risk Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to accurately predict the risk of coronary artery disease (CAD) in patients with Chronic Kidney Disease (CKD) or vice versa, and there is a lack of effective methods to prevent contrast-induced nephropathy in CKD patients undergoing radiological procedures, which poses a significant risk due to impaired renal function.
Innovation Solution
Assaying for elevated levels of bone morphogenic protein-4 (BMP-4) in serum or plasma to predict the presence of CAD or CKD, utilizing an ELISA kit to measure BMP-4 levels, which correlates with increased coronary artery calcification and vascular risk, allowing for differentiation of high-risk patients and potential reduction in contrast media exposure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional risk assessment methods (Framingham Risk Equation) are used to predict cardiovascular disease risk in CKD patients, then the assessment is simple and widely applicable, but the prediction accuracy is insufficient and does not adequately capture the increased risk in CKD patients
Solution Approach 1:
The patent introduces BMP-4 as an intermediary biomarker that mediates between CKD status and cardiovascular risk prediction. BMP-4 levels serve as a mediator that captures the underlying pathophysiological processes (vascular calcification, osteogenic transformation) that traditional risk equations miss, thereby improving prediction accuracy without requiring complex multi-factor assessments
Solution Approach 2:
The patent changes the prediction parameter from traditional cardiovascular risk factors (cholesterol, blood pressure, smoking) to BMP-4 levels, which directly reflect the osteogenic transformation and vascular calcification processes specific to CKD patients. This parameter change enables accurate risk stratification in CKD populations where traditional parameters fail
2Measurement precision
If CKD patients undergo radiological procedures with iodinated contrast media to diagnose CAD, then diagnostic accuracy is improved, but the risk of contrast-induced nephropathy increases significantly
Solution Approach 1:
The patent performs preliminary risk assessment using BMP-4 levels before administering contrast media. By measuring BMP-4 in advance, clinicians can identify high-risk patients who are more susceptible to contrast-induced nephropathy and take preventive measures (such as using alternative imaging modalities or implementing protective protocols) before the harmful exposure occurs
Solution Approach 2:
The patent establishes a feedback mechanism where BMP-4 levels provide information about renal vulnerability and cardiovascular risk, which feeds back into the decision-making process for contrast media administration. This feedback loop enables dynamic risk management, allowing clinicians to adjust diagnostic strategies based on individual patient BMP-4 levels
Data Source
AI summary
The invention is a method of detecting CAD in a CKD diagnosed human patient or CKD in a CAD diagnosed human patient, or detection of the presence of both CKD and CAD by assaying a plasma or serum sample of a human patient for elevated levels of BMP-4.